A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

BACKGROUND. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gold, Kathryn A., Lee, J. Jack, Harun, Nusrat, Tang, Ximing, Price, Justina, Kawedia, Jitesh D., Tran, Hai T., Erasmus, Jeremy J., Blumenschein, George R., William, William N., Wistuba, Ignacio I., Johnson, Faye M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2014
Gaiak:
Clinical Trial Results
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201000/
https://ncbi.nlm.nih.gov/pubmed/25170013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0228
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak